AIM ImmunoTech converts $450,000 note into 1,921,441 shares
AIM ImmunoTech executed two debt-for-equity exchanges with Streeterville Capital on September 3 and 4, 2026, tied to its November 18, 2025 promissory note. Around $450,000 of principal was converted into 1,921,441 shares of common stock at an average price of about…
AIM ImmunoTech said it completed two debt-for-equity exchanges with Streeterville Capital on September 3 and 4, 2026. The transactions were linked to the company’s November 18, 2025 promissory note and converted about $450,000 of principal into 1,921,441 shares of common stock at an average price of about.